Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc., a drug discovery and development company targeting the most potent suppressor pathways in human cancer, along with its collaborators, has been selected to present at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia. The seven abstracts selected for presentation include results of preclinical studies that continue to demonstrate the robust efficacy of ONC201, Oncoceutics’ new oncology drug, in aggressive and refractory cancers. The presentations will also further elucidate the mechanism of action that underpins ONC201’s compelling efficacy and safety profile. Clinical trials for ONC201 are currently underway.
About Oncoceutics
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The first lead compound to result from this program is ONC201, a small molecule drug with a unique mechanism of action that causes significant anti-tumor activity in a variety of types of human cancer. The Company is currently enrolling patients in clinical trials of ONC201, which began in January 2015, following acceptance by the U.S. Food and Drug Administration of the Company’s Investigational New Drug (IND) application for ONC201 in 2014. Oncoceutics and collaborative groups have received approximately $5 million in grants over the last two years from the National Institutes of Health, the Pennsylvania Department of Health, and The Musella Foundation, and the company has leveraged additional funding from academic medical research partners that support multiple Phase I/II clinical trials.
Visit Oncoceutics or contact Rohinton Tarapore for more information.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.